{ "FullStudy":{ "Rank":217887, "Study":{ "ProtocolSection":{ "IdentificationModule":{ "NCTId":"NCT01515540", "OrgStudyIdInfo":{ "OrgStudyId":"STU00022968" }, "Organization":{ "OrgFullName":"Northwestern University", "OrgClass":"OTHER" }, "BriefTitle":"Brain Imaging of Lidoderm for Chronic Back Pain", "OfficialTitle":"Brain Imaging of Lidoderm for Chronic Back Pain" }, "StatusModule":{ "StatusVerifiedDate":"July 2013", "OverallStatus":"Completed", "ExpandedAccessInfo":{ "HasExpandedAccess":"No" }, "StartDateStruct":{ "StartDate":"January 2004" }, "PrimaryCompletionDateStruct":{ "PrimaryCompletionDate":"June 2010", "PrimaryCompletionDateType":"Actual" }, "CompletionDateStruct":{ "CompletionDate":"June 2010", "CompletionDateType":"Actual" }, "StudyFirstSubmitDate":"January 18, 2012", "StudyFirstSubmitQCDate":"January 23, 2012", "StudyFirstPostDateStruct":{ "StudyFirstPostDate":"January 24, 2012", "StudyFirstPostDateType":"Estimate" }, "ResultsFirstSubmitDate":"October 16, 2012", "ResultsFirstSubmitQCDate":"July 23, 2013", "ResultsFirstPostDateStruct":{ "ResultsFirstPostDate":"July 30, 2013", "ResultsFirstPostDateType":"Estimate" }, "LastUpdateSubmitDate":"July 23, 2013", "LastUpdatePostDateStruct":{ "LastUpdatePostDate":"July 30, 2013", "LastUpdatePostDateType":"Estimate" } }, "SponsorCollaboratorsModule":{ "ResponsibleParty":{ "ResponsiblePartyType":"Principal Investigator", "ResponsiblePartyInvestigatorFullName":"Apkar Apkarian", "ResponsiblePartyInvestigatorTitle":"Professor", "ResponsiblePartyInvestigatorAffiliation":"Northwestern University" }, "LeadSponsor":{ "LeadSponsorName":"Northwestern University", "LeadSponsorClass":"OTHER" }, "CollaboratorList":{ "Collaborator":[ { "CollaboratorName":"Endo Pharmaceuticals", "CollaboratorClass":"INDUSTRY" } ] } }, "OversightModule":{ "OversightHasDMC":"No" }, "DescriptionModule":{ "BriefSummary":"The investigators tested whether pain decrease can be observed centrally with non-invasive brain imaging in CBP subjects receiving Lidoderm. The investigators first tested effects of 5% Lidoderm patched in an open labelled trial. Next the investigators compared the effects of Lidocaine versus Placebo patches. Three time points were evaluated: baseline (before treatment) and 6 hours and 2 weeks after treatment. The latter trial was a 2 arm, double blind, placebo controlled trial, where participants either received Lidoderm or placebo patches, without cross over.", "DetailedDescription":"Previous data showed that Lidoderm patches that contain 5% Lidocaine applied to the affected area for a period of 1-2 weeks decreased chronic pain. We conducted a preliminary open-label trial in chronic back pain patients and found that the patients reported reduction in pain intensity and associated brain activity (measured with fMRI). As a next step, we conducted a double blind clinical trial where the drug was tested against placebo to determine whether the effects on CBP were mediated by a pharmacological mechanism. For this we obtained psychophysical measurements of pain and measures of brain activity using fMRI. Two scans after treatment (6 hour and 2 weeks after treatment) were conducted to observe the effects of short term and long term use.\n\nBrain activity was measured by the non-invasive method of functional imaging (fMRI), which enables examination of cortical blood flow during pain rating. These brain scans were acquired in chronic back pain patients while they rated their ongoing chronic pain using a finger span device. In a control task, each patient also rated the changes in the length of a bar n a screen (a visual control task). Anatomical scans were also acquired.\n\nThe general design of the study was that CBP subjects were assesses with fmri for brain responses for ongoing pain at three time points. The initial (baseline) scan occurred after a minimum of 48 hour period during which the patients refrained from taking analgesic medication. The patients were next scanned at 6 hours after treatment and again after 2 weeks of continuous treatment. Subjects were randomised to placebo or Lidoderm (both Lidoderm and placebo patches were supplied by Endo Pharmaceuticals)." }, "ConditionsModule":{ "ConditionList":{ "Condition":[ "Low Back Pain" ] }, "KeywordList":{ "Keyword":[ "chronic back pain", "placebo", "fmri", "brain imaging" ] } }, "DesignModule":{ "StudyType":"Interventional", "PhaseList":{ "Phase":[ "Phase 4" ] }, "DesignInfo":{ "DesignAllocation":"Randomized", "DesignInterventionModel":"Parallel Assignment", "DesignPrimaryPurpose":"Basic Science", "DesignMaskingInfo":{ "DesignMasking":"Triple", "DesignWhoMaskedList":{ "DesignWhoMasked":[ "Participant", "Investigator", "Outcomes Assessor" ] } } }, "EnrollmentInfo":{ "EnrollmentCount":"38", "EnrollmentType":"Actual" } }, "ArmsInterventionsModule":{ "ArmGroupList":{ "ArmGroup":[ { "ArmGroupLabel":"lidocaine", "ArmGroupType":"Active Comparator", "ArmGroupDescription":"5% lidoderm patch", "ArmGroupInterventionList":{ "ArmGroupInterventionName":[ "Drug: lidocaine" ] } },{ "ArmGroupLabel":"control", "ArmGroupType":"Placebo Comparator", "ArmGroupDescription":"placebo patch", "ArmGroupInterventionList":{ "ArmGroupInterventionName":[ "Drug: placebo" ] } } ] }, "InterventionList":{ "Intervention":[ { "InterventionType":"Drug", "InterventionName":"lidocaine", "InterventionDescription":"5% lidoderm patch", "InterventionArmGroupLabelList":{ "InterventionArmGroupLabel":[ "lidocaine" ] }, "InterventionOtherNameList":{ "InterventionOtherName":[ "Lidoderm (Endo Pharmaceuticals)", "5% lidocaine patch" ] } },{ "InterventionType":"Drug", "InterventionName":"placebo", "InterventionDescription":"placebo", "InterventionArmGroupLabelList":{ "InterventionArmGroupLabel":[ "control" ] }, "InterventionOtherNameList":{ "InterventionOtherName":[ "sham patch" ] } } ] } }, "OutcomesModule":{ "PrimaryOutcomeList":{ "PrimaryOutcome":[ { "PrimaryOutcomeMeasure":"Pain Intensity on a Visual Analog Scale (VAS) The Scale Had Values From 0-100, Where 0 Represents \"no Pain\" and 100 Was the \"Worst Pain Imaginable\".", "PrimaryOutcomeDescription":"the primary hypothesis was that the lidoderm 5% patch was expected to decrease pain intensity post treatment greater than placebo patch.\n\nA lower value on the 0-100 scale is considered to represent less pain. Higher values represent more pain. Greater than 20%-30% decrease in pain is considered clinically meaningful.", "PrimaryOutcomeTimeFrame":"2 weeks" } ] } }, "EligibilityModule":{ "EligibilityCriteria":"Inclusion Criteria:\n\nMale or Female 18 years or older of age\nPain in the location of the lower back\nPain duration for a minimum of 6 months on a continuous basis\nPain intensity of at least 3 out of 10 on most days of the week over the past six months\nManifestations of radicular element of pain: radiation below knee (examples towards thigh, buttocks).\nRight handedness\n\nExclusion Criteria:\n\nApplying for or currently receiving workers' compensation or disability status.\nBack pain secondary to spinal cord injury\nBack pain secondary to any systemic condition (e.g ankylosing spondylitis0\nDiabetes mellitus\nBack pain secondary to tumors.\nStandard MRI criteria re: claustrophobia, metal objects etc.\nSubjects with cognitive deficits such as dementia, psychiatric illness including depression with a BDI score of more than 19 (moderate to severe depression), history of brain injury, history of chronic disease\nPregnant and/or lactating women\nLeft handedness\nActive cancer\nOther serious painful condition (e.g., arthritis)", "HealthyVolunteers":"Accepts Healthy Volunteers", "Gender":"All", "MinimumAge":"18 Years", "StdAgeList":{ "StdAge":[ "Adult", "Older Adult" ] } }, "ContactsLocationsModule":{ "OverallOfficialList":{ "OverallOfficial":[ { "OverallOfficialName":"Apkar V. Apkarian, PhD", "OverallOfficialAffiliation":"Northwestern University", "OverallOfficialRole":"Principal Investigator" } ] }, "LocationList":{ "Location":[ { "LocationFacility":"Northwestern University", "LocationCity":"Chicago", "LocationState":"Illinois", "LocationZip":"60611", "LocationCountry":"United States" } ] } }, "ReferencesModule":{ "ReferenceList":{ "Reference":[ { "ReferencePMID":"18950528", "ReferenceType":"result", "ReferenceCitation":"Baliki MN, Geha PY, Jabakhanji R, Harden N, Schnitzer TJ, Apkarian AV. A preliminary fMRI study of analgesic treatment in chronic back pain and knee osteoarthritis. Mol Pain. 2008 Oct 25;4:47. doi: 10.1186/1744-8069-4-47." } ] } } }, "ResultsSection":{ "ParticipantFlowModule":{ "FlowRecruitmentDetails":"38 patients were recruited for the brain imaging and treatment study. Data from 7 subjects was not analyzed due to failure to attend the repeat sessions for non specific reasons and data from 1 subject was excluded from analysis due to technical faults. Thus, data from a total of 30 subjects was included in the brain imaging analysis.", "FlowGroupList":{ "FlowGroup":[ { "FlowGroupId":"FG000", "FlowGroupTitle":"Lidocaine", "FlowGroupDescription":"5% lidoderm patch" },{ "FlowGroupId":"FG001", "FlowGroupTitle":"Control", "FlowGroupDescription":"placebo patch" } ] }, "FlowPeriodList":{ "FlowPeriod":[ { "FlowPeriodTitle":"Overall Study", "FlowMilestoneList":{ "FlowMilestone":[ { "FlowMilestoneType":"STARTED", "FlowAchievementList":{ "FlowAchievement":[ { "FlowAchievementGroupId":"FG000", "FlowAchievementNumSubjects":"20" },{ "FlowAchievementGroupId":"FG001", "FlowAchievementNumSubjects":"18" } ] } },{ "FlowMilestoneType":"COMPLETED", "FlowAchievementList":{ "FlowAchievement":[ { "FlowAchievementGroupId":"FG000", "FlowAchievementNumSubjects":"15" },{ "FlowAchievementGroupId":"FG001", "FlowAchievementNumSubjects":"15" } ] } },{ "FlowMilestoneType":"NOT COMPLETED", "FlowAchievementList":{ "FlowAchievement":[ { "FlowAchievementGroupId":"FG000", "FlowAchievementNumSubjects":"5" },{ "FlowAchievementGroupId":"FG001", "FlowAchievementNumSubjects":"3" } ] } } ] } } ] } }, "BaselineCharacteristicsModule":{ "BaselineGroupList":{ "BaselineGroup":[ { "BaselineGroupId":"BG000", "BaselineGroupTitle":"Lidocaine", "BaselineGroupDescription":"5% lidoderm patch" },{ "BaselineGroupId":"BG001", "BaselineGroupTitle":"Control", "BaselineGroupDescription":"placebo patch" },{ "BaselineGroupId":"BG002", "BaselineGroupTitle":"Total", "BaselineGroupDescription":"Total of all reporting groups" } ] }, "BaselineDenomList":{ "BaselineDenom":[ { "BaselineDenomUnits":"Participants", "BaselineDenomCountList":{ "BaselineDenomCount":[ { "BaselineDenomCountGroupId":"BG000", "BaselineDenomCountValue":"20" },{ "BaselineDenomCountGroupId":"BG001", "BaselineDenomCountValue":"18" },{ "BaselineDenomCountGroupId":"BG002", "BaselineDenomCountValue":"38" } ] } } ] }, "BaselineMeasureList":{ "BaselineMeasure":[ { "BaselineMeasureTitle":"Age, Categorical", "BaselineMeasureParamType":"Count of Participants", "BaselineMeasureUnitOfMeasure":"Participants", "BaselineClassList":{ "BaselineClass":[ { "BaselineCategoryList":{ "BaselineCategory":[ { "BaselineCategoryTitle":"<=18 years", "BaselineMeasurementList":{ "BaselineMeasurement":[ { "BaselineMeasurementGroupId":"BG000", "BaselineMeasurementValue":"0" },{ "BaselineMeasurementGroupId":"BG001", "BaselineMeasurementValue":"0" },{ "BaselineMeasurementGroupId":"BG002", "BaselineMeasurementValue":"0" } ] } },{ "BaselineCategoryTitle":"Between 18 and 65 years", "BaselineMeasurementList":{ "BaselineMeasurement":[ { "BaselineMeasurementGroupId":"BG000", "BaselineMeasurementValue":"20" },{ "BaselineMeasurementGroupId":"BG001", "BaselineMeasurementValue":"18" },{ "BaselineMeasurementGroupId":"BG002", "BaselineMeasurementValue":"38" } ] } },{ "BaselineCategoryTitle":">=65 years", "BaselineMeasurementList":{ "BaselineMeasurement":[ { "BaselineMeasurementGroupId":"BG000", "BaselineMeasurementValue":"0" },{ "BaselineMeasurementGroupId":"BG001", "BaselineMeasurementValue":"0" },{ "BaselineMeasurementGroupId":"BG002", "BaselineMeasurementValue":"0" } ] } } ] } } ] } },{ "BaselineMeasureTitle":"Age Continuous", "BaselineMeasureParamType":"Mean", "BaselineMeasureDispersionType":"Standard Deviation", "BaselineMeasureUnitOfMeasure":"years", "BaselineClassList":{ "BaselineClass":[ { "BaselineCategoryList":{ "BaselineCategory":[ { "BaselineMeasurementList":{ "BaselineMeasurement":[ { "BaselineMeasurementGroupId":"BG000", "BaselineMeasurementValue":"53", "BaselineMeasurementSpread":"7.7" },{ "BaselineMeasurementGroupId":"BG001", "BaselineMeasurementValue":"49.73", "BaselineMeasurementSpread":"10.27" },{ "BaselineMeasurementGroupId":"BG002", "BaselineMeasurementValue":"51.36", "BaselineMeasurementSpread":"9.1" } ] } } ] } } ] } },{ "BaselineMeasureTitle":"Sex: Female, Male", "BaselineMeasureParamType":"Count of Participants", "BaselineMeasureUnitOfMeasure":"Participants", "BaselineClassList":{ "BaselineClass":[ { "BaselineCategoryList":{ "BaselineCategory":[ { "BaselineCategoryTitle":"Female", "BaselineMeasurementList":{ "BaselineMeasurement":[ { "BaselineMeasurementGroupId":"BG000", "BaselineMeasurementValue":"8" },{ "BaselineMeasurementGroupId":"BG001", "BaselineMeasurementValue":"9" },{ "BaselineMeasurementGroupId":"BG002", "BaselineMeasurementValue":"17" } ] } },{ "BaselineCategoryTitle":"Male", "BaselineMeasurementList":{ "BaselineMeasurement":[ { "BaselineMeasurementGroupId":"BG000", "BaselineMeasurementValue":"12" },{ "BaselineMeasurementGroupId":"BG001", "BaselineMeasurementValue":"9" },{ "BaselineMeasurementGroupId":"BG002", "BaselineMeasurementValue":"21" } ] } } ] } } ] } },{ "BaselineMeasureTitle":"Region of Enrollment", "BaselineMeasureParamType":"Number", "BaselineMeasureUnitOfMeasure":"participants", "BaselineClassList":{ "BaselineClass":[ { "BaselineClassTitle":"United States", "BaselineCategoryList":{ "BaselineCategory":[ { "BaselineMeasurementList":{ "BaselineMeasurement":[ { "BaselineMeasurementGroupId":"BG000", "BaselineMeasurementValue":"20" },{ "BaselineMeasurementGroupId":"BG001", "BaselineMeasurementValue":"18" },{ "BaselineMeasurementGroupId":"BG002", "BaselineMeasurementValue":"38" } ] } } ] } } ] } } ] } }, "OutcomeMeasuresModule":{ "OutcomeMeasureList":{ "OutcomeMeasure":[ { "OutcomeMeasureType":"Primary", "OutcomeMeasureTitle":"Pain Intensity on a Visual Analog Scale (VAS) The Scale Had Values From 0-100, Where 0 Represents \"no Pain\" and 100 Was the \"Worst Pain Imaginable\".", "OutcomeMeasureDescription":"the primary hypothesis was that the lidoderm 5% patch was expected to decrease pain intensity post treatment greater than placebo patch.\n\nA lower value on the 0-100 scale is considered to represent less pain. Higher values represent more pain. Greater than 20%-30% decrease in pain is considered clinically meaningful.", "OutcomeMeasurePopulationDescription":"based on a literature search.", "OutcomeMeasureReportingStatus":"Posted", "OutcomeMeasureParamType":"Mean", "OutcomeMeasureDispersionType":"Standard Deviation", "OutcomeMeasureUnitOfMeasure":"peak pain intensity", "OutcomeMeasureTimeFrame":"2 weeks", "OutcomeGroupList":{ "OutcomeGroup":[ { "OutcomeGroupId":"OG000", "OutcomeGroupTitle":"Lidocaine", "OutcomeGroupDescription":"5% lidoderm patch" },{ "OutcomeGroupId":"OG001", "OutcomeGroupTitle":"Control", "OutcomeGroupDescription":"placebo patch" } ] }, "OutcomeDenomList":{ "OutcomeDenom":[ { "OutcomeDenomUnits":"Participants", "OutcomeDenomCountList":{ "OutcomeDenomCount":[ { "OutcomeDenomCountGroupId":"OG000", "OutcomeDenomCountValue":"15" },{ "OutcomeDenomCountGroupId":"OG001", "OutcomeDenomCountValue":"15" } ] } } ] }, "OutcomeClassList":{ "OutcomeClass":[ { "OutcomeCategoryList":{ "OutcomeCategory":[ { "OutcomeMeasurementList":{ "OutcomeMeasurement":[ { "OutcomeMeasurementGroupId":"OG000", "OutcomeMeasurementValue":"51.0", "OutcomeMeasurementSpread":"7.6" },{ "OutcomeMeasurementGroupId":"OG001", "OutcomeMeasurementValue":"51.6", "OutcomeMeasurementSpread":"7.1" } ] } } ] } } ] } } ] } }, "AdverseEventsModule":{ "EventsFrequencyThreshold":"0", "EventsTimeFrame":"2 weeks", "EventGroupList":{ "EventGroup":[ { "EventGroupId":"EG000", "EventGroupTitle":"Lidocaine", "EventGroupDescription":"5% lidoderm patch", "EventGroupSeriousNumAffected":"0", "EventGroupSeriousNumAtRisk":"20", "EventGroupOtherNumAffected":"0", "EventGroupOtherNumAtRisk":"20" },{ "EventGroupId":"EG001", "EventGroupTitle":"Control", "EventGroupDescription":"placebo patch", "EventGroupSeriousNumAffected":"0", "EventGroupSeriousNumAtRisk":"18", "EventGroupOtherNumAffected":"0", "EventGroupOtherNumAtRisk":"18" } ] } }, "MoreInfoModule":{ "CertainAgreement":{ "AgreementPISponsorEmployee":"No", "AgreementRestrictiveAgreement":"No" }, "PointOfContact":{ "PointOfContactTitle":"Javeria Ali Hashmi", "PointOfContactOrganization":"Northwestern University", "PointOfContactEMail":"j-hashmi@northwestern.edu", "PointOfContactPhone":"3125037991" } } }, "DerivedSection":{ "MiscInfoModule":{ "VersionHolder":"April 22, 2020" }, "InterventionBrowseModule":{ "InterventionMeshList":{ "InterventionMesh":[ { "InterventionMeshId":"D000008012", "InterventionMeshTerm":"Lidocaine" } ] }, "InterventionAncestorList":{ "InterventionAncestor":[ { "InterventionAncestorId":"D000000779", "InterventionAncestorTerm":"Anesthetics, Local" },{ "InterventionAncestorId":"D000000777", "InterventionAncestorTerm":"Anesthetics" },{ "InterventionAncestorId":"D000002492", "InterventionAncestorTerm":"Central Nervous System Depressants" },{ "InterventionAncestorId":"D000045505", "InterventionAncestorTerm":"Physiological Effects of Drugs" },{ "InterventionAncestorId":"D000018689", "InterventionAncestorTerm":"Sensory System Agents" },{ "InterventionAncestorId":"D000018373", "InterventionAncestorTerm":"Peripheral Nervous System Agents" },{ "InterventionAncestorId":"D000000889", "InterventionAncestorTerm":"Anti-Arrhythmia Agents" },{ "InterventionAncestorId":"D000061567", "InterventionAncestorTerm":"Voltage-Gated Sodium Channel Blockers" },{ "InterventionAncestorId":"D000026941", "InterventionAncestorTerm":"Sodium Channel Blockers" },{ "InterventionAncestorId":"D000049990", "InterventionAncestorTerm":"Membrane Transport Modulators" },{ "InterventionAncestorId":"D000045504", "InterventionAncestorTerm":"Molecular Mechanisms of Pharmacological Action" } ] }, "InterventionBrowseLeafList":{ "InterventionBrowseLeaf":[ { "InterventionBrowseLeafId":"M9597", "InterventionBrowseLeafName":"Lidocaine", "InterventionBrowseLeafAsFound":"Lidocaine", "InterventionBrowseLeafRelevance":"high" },{ "InterventionBrowseLeafId":"M2688", "InterventionBrowseLeafName":"Anesthetics", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M2690", "InterventionBrowseLeafName":"Anesthetics, Local", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M2794", "InterventionBrowseLeafName":"Anti-Arrhythmia Agents", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M28612", "InterventionBrowseLeafName":"Diuretics, Potassium Sparing", "InterventionBrowseLeafRelevance":"low" },{ "InterventionBrowseLeafId":"M21761", "InterventionBrowseLeafName":"Sodium Channel Blockers", "InterventionBrowseLeafRelevance":"low" } ] }, "InterventionBrowseBranchList":{ "InterventionBrowseBranch":[ { "InterventionBrowseBranchAbbrev":"AnArAg", "InterventionBrowseBranchName":"Anti-Arrhythmia Agents" },{ "InterventionBrowseBranchAbbrev":"ChanBlk", "InterventionBrowseBranchName":"Channel Blockers" },{ "InterventionBrowseBranchAbbrev":"CNSDep", "InterventionBrowseBranchName":"Central Nervous System Depressants" },{ "InterventionBrowseBranchAbbrev":"All", "InterventionBrowseBranchName":"All Drugs and Chemicals" } ] } }, "ConditionBrowseModule":{ "ConditionMeshList":{ "ConditionMesh":[ { "ConditionMeshId":"D000001416", "ConditionMeshTerm":"Back Pain" },{ "ConditionMeshId":"D000017116", "ConditionMeshTerm":"Low Back Pain" } ] }, "ConditionAncestorList":{ "ConditionAncestor":[ { "ConditionAncestorId":"D000010146", "ConditionAncestorTerm":"Pain" },{ "ConditionAncestorId":"D000009461", "ConditionAncestorTerm":"Neurologic Manifestations" },{ "ConditionAncestorId":"D000012816", "ConditionAncestorTerm":"Signs and Symptoms" } ] }, "ConditionBrowseLeafList":{ "ConditionBrowseLeaf":[ { "ConditionBrowseLeafId":"M3295", "ConditionBrowseLeafName":"Back Pain", "ConditionBrowseLeafAsFound":"Back Pain", "ConditionBrowseLeafRelevance":"high" },{ "ConditionBrowseLeafId":"M18016", "ConditionBrowseLeafName":"Low Back Pain", "ConditionBrowseLeafAsFound":"Low Back Pain", "ConditionBrowseLeafRelevance":"high" },{ "ConditionBrowseLeafId":"M11649", "ConditionBrowseLeafName":"Pain", "ConditionBrowseLeafRelevance":"low" },{ "ConditionBrowseLeafId":"M10987", "ConditionBrowseLeafName":"Neurologic Manifestations", "ConditionBrowseLeafRelevance":"low" } ] }, "ConditionBrowseBranchList":{ "ConditionBrowseBranch":[ { "ConditionBrowseBranchAbbrev":"BC23", "ConditionBrowseBranchName":"Symptoms and General Pathology" },{ "ConditionBrowseBranchAbbrev":"All", "ConditionBrowseBranchName":"All Conditions" },{ "ConditionBrowseBranchAbbrev":"BC10", "ConditionBrowseBranchName":"Nervous System Diseases" } ] } } } } } }